Transfection News and Research

RSS

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers used a SARS-CoV-2 spike protein-pseudotyped viral model to characterize BA.2.86 variant neutralization by monoclonal antibodies.

6 Sep 2023

Innovate UK funding to support the development of powdered gene therapy for bone graft augmentation

TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, and its collaborator, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK, the UK’s innovation agency.

4 Sep 2023

TherageniX and University of Nottingham awarded £995K Innovate UK grant to develop powdered gene therapy for bone regeneration

Funding from Innovate UK’s Transforming Medicines Manufacturing program supporting innovative technologies for intracellular drug delivery.

1 Sep 2023

Unleashing the Power of Microfluidic Picodroplets

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Richard Hammond, Chief Technical Officer at Sphere Fluidics, about Sphere Fluidic's microfluidic picodroplet technology and more.

From Sphere Fluidics 21 Aug 2023

MaxCyte signs strategic platform license with Lyell Immunopharma

From MaxCyte, Inc. 10 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

From MaxCyte, Inc. 10 Aug 2023

Nanotechnology's triple threat: Advancing precision cancer treatment

The design of tumor tissue-, cell-, and organelle-targeted cancer nanomedicines.

9 Aug 2023

SARS-CoV-2 spike pseudovirion infection in ARPE-19 cells is a dynamin-dependent process that is primarily mediated by LDLR

Researchers reported on lentiviral pseudovirions pseudotyped with SARS-CoV-2.

1 Aug 2023

Researchers demonstrate targeted epigenome editing in the promoter region of several genes using sgRNA/dCas9 complexes

Researchers develop and characterize a highly specific EpiEditing system using catalytically inactivated catalytically inactivated Cas9.

17 Jul 2023

Researcher from Wageningen University wins Green CellDrop Giveaway

DeNovix Inc. is pleased to announce the winner of the Green CellDrop Automated Cell Counter Giveaway: Michiel Schrijen from Wageningen University, Netherlands! Selected at random from thousands of entries from scientists worldwide, the CellDrop will be housed in the Biosystematics Group at the university.

From DeNovix Inc. 29 Jun 2023

Catalent expands OneBio® suite for integrated development, manufacturing and supply across biologic modalities

Catalen today announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.

From Catalent 16 Jun 2023

Novel 'CLEVER' method accelerates engineering and genetic study of SARS-CoV-2 and its variants

Researchers described rapid mutagenesis and rescue of SARS-CoV-2 variants without cloning.

16 May 2023

Print your own vaccine: automatic printing of microneedle patch COVID-19 mRNA vaccines

Researchers reported on the automatic printing of microneedle patch SARS-CoV-2 mRNA vaccines.

26 Apr 2023

FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing

Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses.

From FUJIFILM Irvine Scientific 11 Apr 2023

Tetravalent COVID vaccine provides broad antibody responses against SARS-CoV-2 variants in animal model

In a recent study posted to the bioRxiv* preprint server, researchers in Italy and the United States evaluated the efficacy and immunogenicity of an adjuvanted tetravalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit 1 (S1) COVID-19 vaccine.

21 Mar 2023

Oral host responses to SARS-CoV-2 predict progression of COVID-19

In a recent study posted to the medRxiv* preprint server, researchers at the University of North Carolina and the National Institutes of Health determined the associations between oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), oral antibodies against SARS-CoV-2, and coronavirus disease 2019 (COVID-19) symptoms.

14 Mar 2023

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Researchers from The University of Texas MD Anderson Cancer Center have developed fully human bispecific antibodies, as revealed in a recent study. These antibodies can bind to two distinct epitopes of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and have demonstrated the ability to neutralize various strains of the virus, including the Omicron variant.

14 Mar 2023

NQO2 gene as a novel potential target in Parkinson’s disease

A new study under review at the journal Scientific Reports and currently available on the Research Square* preprint server aimed to analyze the toxic effects of 6OHDA along with a related role of NQO2 in murine and human astrocytes.

23 Feb 2023

DeNovix celebrates sustainability award with Green CellDrop™ Automated Cell Counter Giveaway

DeNovix Inc. is giving away a Green CellDrop™ Automated Cell Counter to celebrate the instrument’s new Sustainable Laboratory Product of the Year award from SelectScience.

From DeNovix Inc. 15 Feb 2023

Transfection News and Research

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Innovate UK funding to support the development of powdered gene therapy for bone graft augmentation

TherageniX and University of Nottingham awarded £995K Innovate UK grant to develop powdered gene therapy for bone regeneration

Unleashing the Power of Microfluidic Picodroplets

MaxCyte signs strategic platform license with Lyell Immunopharma

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

Nanotechnology's triple threat: Advancing precision cancer treatment

SARS-CoV-2 spike pseudovirion infection in ARPE-19 cells is a dynamin-dependent process that is primarily mediated by LDLR

Researchers demonstrate targeted epigenome editing in the promoter region of several genes using sgRNA/dCas9 complexes

Researcher from Wageningen University wins Green CellDrop Giveaway

Catalent expands OneBio® suite for integrated development, manufacturing and supply across biologic modalities

Novel 'CLEVER' method accelerates engineering and genetic study of SARS-CoV-2 and its variants

Print your own vaccine: automatic printing of microneedle patch COVID-19 mRNA vaccines

FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing

Tetravalent COVID vaccine provides broad antibody responses against SARS-CoV-2 variants in animal model

Oral host responses to SARS-CoV-2 predict progression of COVID-19

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

NQO2 gene as a novel potential target in Parkinson’s disease

DeNovix celebrates sustainability award with Green CellDrop™ Automated Cell Counter Giveaway

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News